We are live on ! Find out more
RCUS icon

Arcus Biosciences
RCUS

179 hedge funds and large institutions have $1.01B invested in Arcus Biosciences in 2023 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 70 increasing their positions, 60 reducing their positions, and 43 closing their positions.

New
Increased
Maintained
Reduced
Closed

37% more call options, than puts

Call options by funds: $10.2M | Put options by funds: $7.43M

17% more repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 60

1.66% more ownership

Funds ownership: 74.27% → 75.93% (+1.7%)

7% less capital invested

Capital invested by funds: $1.09B → $1.01B (-$79.4M)

11% less funds holding

Funds holding: 200 → 179 (-21)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

44% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 43

Holders
179
Holders Change
-21
Holders Change %
-10.5%
% of All Funds
2.85%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
24
Increased
70
Reduced
60
Closed
43
Calls
$10.2M
Puts
$7.43M
Net Calls
+$2.75M
Net Calls Change
+$10.9M

Top Buyers

1
State Street
State Street
Massachusetts
+$37.3M
2
Citadel Advisors
Citadel Advisors
Florida
+$21.5M
3
Bank of America
Bank of America
North Carolina
+$19.3M
4
BlackRock
BlackRock
New York
+$14.3M
5
Walleye Capital
Walleye Capital
New York
+$7.94M

Top Sellers

1
BI
BVF Inc
California
-$47.6M
2
WP
Woodline Partners
California
-$24.8M
3
PHS
PFM Health Sciences
California
-$21.9M
4
FAM
Fred Alger Management
New York
-$11M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$8.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
Walleye Capital
26
Walleye Capital
New York
$7.58M +$7.94M +415,687 New
UBS AM
27
UBS AM
Illinois
$7.5M +$182K +9,531 +2%
Rafferty Asset Management
28
Rafferty Asset Management
New York
$7.5M +$4.13M +215,967 +111%
Macquarie Group
29
Macquarie Group
Australia
$6.92M – – –
Verition Fund Management
30
Verition Fund Management
Connecticut
$6.53M +$6.35M +332,146 +1,285%
Citigroup
31
Citigroup
New York
$6.42M +$4.31M +225,255 +178%
Principal Financial Group
32
Principal Financial Group
Iowa
$5.92M -$81.6K -4,267 -1%
SSA
33
Schonfeld Strategic Advisors
New York
$5.36M +$2.67M +139,471 +90%
SAM
34
Sectoral Asset Management
Quebec, Canada
$5.36M +$1.05M +55,164 +23%
Invesco
35
Invesco
Georgia
$5.16M +$207K +10,841 +4%
T. Rowe Price Associates
36
T. Rowe Price Associates
Maryland
$5.1M -$4.32M -226,217 -45%
Schroder Investment Management Group
37
Schroder Investment Management Group
United Kingdom
$4.83M +$2.85M +148,932 +128%
Nordea Investment Management
38
Nordea Investment Management
Sweden
$4.81M -$46.4K -2,428 -0.9%
Susquehanna International Group
39
Susquehanna International Group
Pennsylvania
$4.78M +$3.44M +180,110 +220%
PAM
40
Panagora Asset Management
Massachusetts
$4.61M +$1.06M +55,384 +28%
EAM
41
Eventide Asset Management
Massachusetts
$4.38M – – –
PIM
42
Platinum Investment Management
Australia
$4.24M +$1.49M +77,761 +50%
IC
43
Ikarian Capital
Texas
$4.2M +$1.76M +92,013 +67%
GGHC
44
Gilder Gagnon Howe & Co
New York
$4.16M -$205K -10,728 -4%
AQR Capital Management
45
AQR Capital Management
Connecticut
$4.04M +$1.92M +100,293 +83%
BFM
46
Boothbay Fund Management
New York
$3.98M +$3.64M +190,537 +684%
Ameriprise
47
Ameriprise
Minnesota
$3.56M -$173K -9,067 -4%
DCM
48
DAFNA Capital Management
California
$3.2M +$631K +33,000 +23%
RhumbLine Advisers
49
RhumbLine Advisers
Massachusetts
$3.03M +$58.2K +3,044 +2%
BNP Paribas Financial Markets
50
BNP Paribas Financial Markets
France
$2.98M +$2.27M +118,769 +267%
1
2
3 4 5

RCUS Hedge Fund Activity: Q1 2023 in Review

179 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q1 2023, worth a combined $1.01B — down 7.3% from $1.09B a quarter earlier.

Sellers outnumbered buyers: 43 funds closed out of RCUS and 24 opened new positions — a net loss of 19 holders — while 60 trimmed existing stakes and 70 added.

The largest buyer was State Street, adding an estimated $37.3M. The largest seller was BVF Inc, exiting entirely with an estimated $47.6M sold.

  • 179 institutional investors held Arcus Biosciences (RCUS) as of Q1 2023, down from 200 in Q4 2022.
  • Funds reported $1.01B of Arcus Biosciences stock for Q1 2023, down 7.3% quarter-over-quarter.
  • 24 funds opened new Arcus Biosciences positions in Q1 2023 and 43 closed out, a net change of -19 holders.
  • The largest Arcus Biosciences buyer in Q1 2023 was State Street, an estimated $37.3M added.
  • The largest Arcus Biosciences seller in Q1 2023 was BVF Inc, an estimated $47.6M sold.

Based on aggregated 13F filings for Q1 2023.